GO
Loading...

Enter multiple symbols separated by commas

AstraZeneca PLC

More

  • WASHINGTON, April 14- AstraZeneca Plc's diabetes drug Onglyza and Takeda Pharmaceutical Co.' s rival product Nesina should carry information about the risk of heart failure, an advisory committee to the U.S. Food and Drug Administration said on Tuesday. The panel reviewed safety data on AstraZeneca's Onglyza and Takeda's Nesina. The studies were requested by...

  • A preliminary FDA review of Nesina, or alogliptin, showed a numerical increase in heart failure hospitalizations but not a statistically significant increase. Even so, some analysts expect the FDA to treat all drugs in the class the same way. "We believe the FDA will likely view the risk as likely to be a class effect and apply changes to all approved drugs in the...

  • WASHINGTON, April 14- AstraZeneca Plc's diabetes drug Onglyza should include new safety information about the risk of heart failure, a U.S. Food and Drug Administration advisory panel concluded on Tuesday. The FDA is not obliged to follow the advice of its advisory panels but typically does so. A preliminary FDA review of the drug published on Friday noted an...

  • WASHINGTON, April 14- AstraZeneca Plc's diabetes drug Onglyza should include new safety information about the risk of heart failure, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday. The panel voted overwhelmingly that the drug's label should be changed to add information about an increased heart failure risk, but did not...

  • Demand for newer cancer and multiple sclerosis treatments, price increases on branded medicines, particularly insulin products for diabetes, and the entry of few new generic versions of big-selling drugs also contributed to the double-digit spending rise in 2014, the report by IMS Health Holdings Inc found. "We certainly expect to see growth in the market...

  • UK's FTSE races to new record high as Shire shines Friday, 10 Apr 2015 | 11:59 AM ET

    *FTSE 100 up 1.1 pct at record closing high of 7,089.77. *FTSE rises even though election uncertainty hits pound. *FTSE 100 up 8 pct since start of 2015.

  • April 10- AstraZeneca Plc's diabetes drug Onglyza may be associated with an increased rate of death, according to a preliminary review of data by the U.S. Food and Drug Administration. The FDA's report, posted on the agency's website on Friday, comes ahead of an April 14 meeting of an FDA advisory panel to discuss the drug's safety. The FDA said the causes of death...

  • Britain's FTSE nears record high as Shire shines Friday, 10 Apr 2015 | 9:11 AM ET

    *FTSE 100 up 0.5 pct, near record highs. The FTSE 100 rose 0.5 percent to 7,051.07 points, close to a record 7,065.08 points reached in March. Shire shares rose 5.2 percent, the biggest gain on the FTSE 100, from a U.S. Food and Drug Administration decision to grant a priority review to its application for lifitegrast, a dry-eye disease treatment.

  • Biotech wins $45 million grant for Ebola vaccine Monday, 6 Apr 2015 | 9:28 AM ET
    Dr. Joseph Kim, founder of Inovio Pharmaceuticals

    Today's vaccine debate will be outdated if Inovio succeeds in developing DNA vaccines. Imagine a single needle shot that can cure Ebola.

  • FRANKFURT, April 1- Roche, the world's largest cancer drugmaker, is ready to collaborate with rivals to find new combination therapies for multi-pronged treatments, its chief executive said. Roche is vying with rivals such as Bristol-Myers Squibb, Merck& Co and AstraZeneca to develop such immuno-oncology therapies that harness the power of the body's immune...

  • Pay rises may be hard to find - if you’re a FTSE CEO Wednesday, 1 Apr 2015 | 3:09 AM ET
    Smelling money bonus

    Here’s a phrase you don’t hear that often: It’s tough out there for the U.K.’s leading chief executives.

  • Drugs companies unite to mine genetic data Thursday, 26 Mar 2015 | 2:25 AM ET

    Major pharmaceuticals companies have formed a partnership with Genomics England in the first step towards using genetic data from NHS patients.

  • *UK acquisitions by foreign buyers total $48 bln year to date. Investors appear relatively unconcerned about the risk of instability after a general election on May 7 or doubts about Britain's future in the European Union. Even excluding a $15 billion bid by Hutchison Whampoa for O2's UK operations, inbound mergers& acquisitions activity so far this year is at...

  • March 24- Merck& Co Inc said on Tuesday that it would stop a large study of its Keytruda melanoma treatment early because an independent monitoring committee determined the drug succeeded in its goal of prolonging survival in previously untreated patients at advanced stage of the disease. The medicine, a PD-1 inhibitor that works by taking the brakes off the...

  • Early movers: MSFT, BID, GE, HPQ, NFLX & more Monday, 16 Mar 2015 | 7:40 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LONDON, March 14- Long-term use of AstraZeneca's drug Brilinta can cut the risk of death, another heart attack or stroke in patients with a history of past attacks by 16 percent, a keenly awaited clinical trial showed on Saturday. The finding may boost sales of the blood-thinner, which AstraZeneca is relying on to drive growth, although doctors must balance its...

  • Why biotech investors may be hurting innovation Friday, 13 Mar 2015 | 3:27 PM ET
    Biotech

    Over the past five years, investor money is increasingly moving toward consumer software and later-stage life science ventures, a trend that could help develop new treatments.

  • March 11- Cloud storage provider Box Inc posted a bigger loss due to higher operating expenses, in its first quarterly report as a public company. Founded in 2005 by Levie, a University of Southern California dropout, and his friend Dylan Smith, Box competes with privately-held Dropbox, Google Inc's Drive and Microsoft Corp's OneDrive. Box, whose customers...

  • March 11- Cloud storage provider Box Inc posted a bigger-than-expected loss due to higher operating expenses, in its first quarterly report as a public company. Founded in 2005 by University of Southern California dropout Aaron Levie and his friend Dylan Smith, Box competes with privately-held Dropbox, Google Inc's Drive and Microsoft Corp's OneDrive.

  • LONDON, March 5- AbbVie's $21 billion deal to buy Pharmacyclics shows big pharma's hunger for new drugs at a time when research at smaller biotechnology companies is driving some of the most promising advances in medicine. AbbVie's planned purchase of Pharmacyclics is the largest global pharmaceutical deal of 2015 to date and takes M&A activity in the sector...